Similar articles

• Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA.

  Pinto AL, Lippard SJ. Pinto AL, et al. Biochim Biophys Acta. 1985;780(3):167-80. doi: 10.1016/0304-419x(85)90001-0. Biochim Biophys Acta. 1985. PMID: 3896310 Review. No abstract available.
• Mechanism of action of cis-dichlorodiammineplatinum(II).

  Zwelling LA, Kohn KW. Zwelling LA, et al. Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1439-44. Cancer Treat Rep. 1979. PMID: 387221 Review.
• Unique properties of DNA interstrand cross-links of antitumor oxaliplatin and the effect of chirality of the carrier ligand.

  Kasparkova J, Vojtiskova M, Natile G, Brabec V. Kasparkova J, et al. Chemistry. 2008;14(4):1330-41. doi: 10.1002/chem.200701352. Chemistry. 2008. PMID: 18022972
• Replacement of an NH(3) by an iminoether in transplatin makes an antitumor drug from an inactive compound.

  Leng M, Locker D, Giraud-Panis MJ, Schwartz A, Intini FP, Natile G, Pisano C, Boccarelli A, Giordano D, Coluccia M. Leng M, et al. Mol Pharmacol. 2000 Dec;58(6):1525-35. doi: 10.1124/mol.58.6.1525. Mol Pharmacol. 2000. PMID: 11093793
• Base sequence-independent distorsions induced by interstrand cross-links in cis-diamminedichloroplatinum (II)-modified DNA.

  Malinge JM, Pérez C, Leng M. Malinge JM, et al. Nucleic Acids Res. 1994 Sep 25;22(19):3834-9. doi: 10.1093/nar/22.19.3834. Nucleic Acids Res. 1994. PMID: 7937101 Free PMC article.